1 Genetic Associations With Thalidomide Mediated Venous Thrombotic Events in Myeloma Identified using Targeted Genotyping

MyelomA genetics international consortium

Hajek, R
Goldschmidt, H
Palumbo, A
Cavo, M
Sonneveld, P
Miguel, JS
Chim, CS
Browne, P
Einsele, H
Waage, A
Turesson, I
Spencer, A
Ludwig, H
Houlston, R
Hemminki, K
Morgan, G
Johnsen, HE

January 2012

While the etiology of multiple myeloma (MM) is largely unknown, evidence for an inherited genetic su...

Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma

A. Vacca
C. Scavelli
V. Montefusco
G. Di Pietro
M. Mattioli
S. Bicciato
B. Nico
D. Ribatti
F. Dammacco
A. Neri
P. Corradini

January 2005

PURPOSE: To study the antiangiogenic effect of thalidomide. PATIENTS AND METHODS: The expression...

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens

Lopes-Aguiar, L.
Delamain, M. T.
Brito, A. B. C.
Lourenco, G. J.
Costa, E. F. D.
Oliveira, G. B.
Vassallo, J.
de Souza, C. A.
Lima, C. S. P.

May 2021

sem informação7FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP2011/15089-

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

Johnson, D.C.
Corthals, S.
Ramos, C.
Hoering, A.
Cocks, K.
Dickens, N.J.
Haessler, J.
Goldschmidt, H.
Child, J.A.
Bell, S.E.
Jackson, G.
Baris, D.
Rajkumar, S.V.
Davies, F.E.
Durie, B.G.M.
Crowley, J.
Sonneveld, P.
Van Ness, B.
Morgan, G.J.

December 2008

A venous thromboembolism (VTE) with the subsequent risk of pulmonary embolism is a major concern in ...

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma

Johnson, D.C.
Corthals, S.L.
Walker, B.A.
Ross, F.M.
Gregory, W.M.
Dickens, N.J.
Lokhorst, H.M.
Goldschmidt, H.
Davies, F.E.
Durie, B.G.M.
Van Ness, B.
Child, J.A.
Sonneveld, P.
Morgan, G.J.

March 2011

Purpose: To indentify genetic variation that can modulate and predict the risk of developing thalido...

211 PUBLICATIONS 8,054 CITATIONS SEE PROFILE

Antje Hoering
Kim Cocks
James Anthony Child
Brian Van Ness
Gareth J Morgan
Faith E Davies
Brian G. M. Durie
John Crowley
Pieter Sonneveld
Brian Van Ness
David C Johnson
Sophie Corthals
Christine Ramos
Antje Hoering
Kim Cocks
Nicholas J Dickens

September 2016

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using ...

Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma

Johnson, David C.
Corthals, Sophie L.
Walker, Brian A.
Ross, Fiona M.
Gregory, Walter M.
Dickens, Nicholas J.
Lokhorst, Henk M.
Goldschmidt, Hartmut
Davies, Faith E.
Durie, Brian G. M.
Van Ness, Brian
Child, J. Anthony
Sonneveld, Pieter
Morgan, Gareth J.

March 2011

Purpose To indentify genetic variation that can modulate and predict the risk of developing thalidom...

Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma

Chattopadhyay, Subhayan
Thomsen, Hauke
Yadav, Pankaj
da Silva Filho, Miguel Inacio
Weinhold, Niels
Nöthen, Markus M
Hoffman, Per
Bertsch, Uta
Huhn, Stefanie
Morgan, Gareth J
Goldschmidt, Hartmut
Houlston, Richard
Hemminki, Kari
Försti, Asta

January 2019

Inherited genetic susceptibility to multiple myeloma has been investigated in a number of studies. A...

STUDIES ON THE GENETIC PREDISPOSITION TO COMMON THROMBOTIC DISEASES

L.A. Lotta

February 2012

Common thrombotic diseases (i.e. myocardial infarction, MI; ischemic stroke; deep vein thrombosis, D...

Identification and characterization of DNA sequence variants associated with multiple myeloma

Ali, Mina

January 2018

Multiple myeloma (MM) is the second most common hematologic malignancy. The disease is characterized...

Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma.

Chattopadhyay, S
Thomsen, H
Yadav, P
da Silva Filho, MI
Weinhold, N
Nöthen, MM
Hoffman, P
Bertsch, U
Huhn, S
Morgan, GJ
Goldschmidt, H
Houlston, R
Hemminki, K
Försti, A

January 2019

Inherited genetic susceptibility to multiple myeloma has been investigated in a number of studies. A...

An integrated pharmacogenomic strategy for the definition of thalidomide response signatures in presenting cases of multiple myeloma

Morgan, Gareth J.
Jenner, Matthew W.
Walker, Brian A.
Johnson, David C.
Leone, Paola A.
Ross, Fiona M.
Drayson, Mark T.
Van Ness, Brian G.
Durie, Brian G.
Dickens, Nicholas J.
Child, J. Anthony
Owen, R.G.
Davies, Faith E.

November 2007

Whilst gene expression signatures have been defined that correspond to poor overall survival, the me...

MyelomA Genetics International Consortium.

July 2015

none17siWhile the etiology of multiple myeloma (MM) is largely unknown, evidence for an inherited ge...

Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma

VACCA A
SCAVELLI C
MONTEFUSCO V
DI PIETRO G
NERI A
MATTIOLI M
NICO B
RIBATTI D
DAMMACCO F
CORRADINI P.
BICCIATO, Silvio

January 2005

PurposeTo study the antiangiogenic effect of thalidomide.Patients and MethodsThe expression of key a...

Deciphering genetic susceptibility to multiple myeloma

Went, M

September 2020

Multiple myeloma (MM) is a malignancy characterised by the clonal expansion of plasma cells primaril...

MyelomA genetics international consortium

Hajek, R
Goldschmidt, H
Palumbo, A
Cavo, M
Sonneveld, P
Miguel, JS
Chim, CS
Browne, P
Einsele, H
Waage, A
Turesson, I
Spencer, A
Ludwig, H
Houlston, R
Hemminki, K
Morgan, G
Johnsen, HE

January 2012

While the etiology of multiple myeloma (MM) is largely unknown, evidence for an inherited genetic su...

Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma

A. Vacca
C. Scavelli
V. Montefusco
G. Di Pietro
M. Mattioli
S. Bicciato
B. Nico
D. Ribatti
F. Dammacco
A. Neri
P. Corradini

January 2005

PURPOSE: To study the antiangiogenic effect of thalidomide. PATIENTS AND METHODS: The expression...

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens

Lopes-Aguiar, L.
Delamain, M. T.
Brito, A. B. C.
Lourenco, G. J.
Costa, E. F. D.
Oliveira, G. B.
Vassallo, J.
de Souza, C. A.
Lima, C. S. P.

May 2021

sem informação7FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP2011/15089-

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

Johnson, D.C.
Corthals, S.
Ramos, C.
Hoering, A.
Cocks, K.
Dickens, N.J.
Haessler, J.
Goldschmidt, H.
Child, J.A.
Bell, S.E.
Jackson, G.
Baris, D.
Rajkumar, S.V.
Davies, F.E.
Durie, B.G.M.
Crowley, J.
Sonneveld, P.
Van Ness, B.
Morgan, G.J.

December 2008

A venous thromboembolism (VTE) with the subsequent risk of pulmonary embolism is a major concern in ...

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma

Johnson, D.C.
Corthals, S.L.
Walker, B.A.
Ross, F.M.
Gregory, W.M.
Dickens, N.J.
Lokhorst, H.M.
Goldschmidt, H.
Davies, F.E.
Durie, B.G.M.
Van Ness, B.
Child, J.A.
Sonneveld, P.
Morgan, G.J.

March 2011

Purpose: To indentify genetic variation that can modulate and predict the risk of developing thalido...

211 PUBLICATIONS 8,054 CITATIONS SEE PROFILE

Antje Hoering
Kim Cocks
James Anthony Child
Brian Van Ness
Gareth J Morgan
Faith E Davies
Brian G. M. Durie
John Crowley
Pieter Sonneveld
Brian Van Ness
David C Johnson
Sophie Corthals
Christine Ramos
Antje Hoering
Kim Cocks
Nicholas J Dickens

September 2016

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using ...

Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma

Johnson, David C.
Corthals, Sophie L.
Walker, Brian A.
Ross, Fiona M.
Gregory, Walter M.
Dickens, Nicholas J.
Lokhorst, Henk M.
Goldschmidt, Hartmut
Davies, Faith E.
Durie, Brian G. M.
Van Ness, Brian
Child, J. Anthony
Sonneveld, Pieter
Morgan, Gareth J.

March 2011

Purpose To indentify genetic variation that can modulate and predict the risk of developing thalidom...

Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma

Chattopadhyay, Subhayan
Thomsen, Hauke
Yadav, Pankaj
da Silva Filho, Miguel Inacio
Weinhold, Niels
Nöthen, Markus M
Hoffman, Per
Bertsch, Uta
Huhn, Stefanie
Morgan, Gareth J
Goldschmidt, Hartmut
Houlston, Richard
Hemminki, Kari
Försti, Asta

January 2019

Inherited genetic susceptibility to multiple myeloma has been investigated in a number of studies. A...

STUDIES ON THE GENETIC PREDISPOSITION TO COMMON THROMBOTIC DISEASES

L.A. Lotta

February 2012

Common thrombotic diseases (i.e. myocardial infarction, MI; ischemic stroke; deep vein thrombosis, D...

Identification and characterization of DNA sequence variants associated with multiple myeloma

Ali, Mina

January 2018

Multiple myeloma (MM) is the second most common hematologic malignancy. The disease is characterized...

Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma.

Chattopadhyay, S
Thomsen, H
Yadav, P
da Silva Filho, MI
Weinhold, N
Nöthen, MM
Hoffman, P
Bertsch, U
Huhn, S
Morgan, GJ
Goldschmidt, H
Houlston, R
Hemminki, K
Försti, A

January 2019

Inherited genetic susceptibility to multiple myeloma has been investigated in a number of studies. A...

An integrated pharmacogenomic strategy for the definition of thalidomide response signatures in presenting cases of multiple myeloma

Morgan, Gareth J.
Jenner, Matthew W.
Walker, Brian A.
Johnson, David C.
Leone, Paola A.
Ross, Fiona M.
Drayson, Mark T.
Van Ness, Brian G.
Durie, Brian G.
Dickens, Nicholas J.
Child, J. Anthony
Owen, R.G.
Davies, Faith E.

November 2007

Whilst gene expression signatures have been defined that correspond to poor overall survival, the me...

MyelomA Genetics International Consortium.

July 2015

none17siWhile the etiology of multiple myeloma (MM) is largely unknown, evidence for an inherited ge...

Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma

VACCA A
SCAVELLI C
MONTEFUSCO V
DI PIETRO G
NERI A
MATTIOLI M
NICO B
RIBATTI D
DAMMACCO F
CORRADINI P.
BICCIATO, Silvio

January 2005

PurposeTo study the antiangiogenic effect of thalidomide.Patients and MethodsThe expression of key a...

Deciphering genetic susceptibility to multiple myeloma

Went, M

September 2020

Multiple myeloma (MM) is a malignancy characterised by the clonal expansion of plasma cells primaril...

MyelomA genetics international consortium

Hajek, R
Goldschmidt, H
Palumbo, A
Cavo, M
Sonneveld, P
Miguel, JS
Chim, CS
Browne, P
Einsele, H
Waage, A
Turesson, I
Spencer, A
Ludwig, H
Houlston, R
Hemminki, K
Morgan, G
Johnsen, HE

January 2012

While the etiology of multiple myeloma (MM) is largely unknown, evidence for an inherited genetic su...

Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma

A. Vacca
C. Scavelli
V. Montefusco
G. Di Pietro
M. Mattioli
S. Bicciato
B. Nico
D. Ribatti
F. Dammacco
A. Neri
P. Corradini

January 2005

PURPOSE: To study the antiangiogenic effect of thalidomide. PATIENTS AND METHODS: The expression...

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens

Lopes-Aguiar, L.
Delamain, M. T.
Brito, A. B. C.
Lourenco, G. J.
Costa, E. F. D.
Oliveira, G. B.
Vassallo, J.
de Souza, C. A.
Lima, C. S. P.

May 2021

sem informação7FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP2011/15089-

1 Genetic Associations With Thalidomide Mediated Venous Thrombotic Events in Myeloma Identified using Targeted Genotyping

Abstract

Extracted data

Related items

Related items